Jack Su is an Oncology physician affiliated with Baylor University. OpenAlex indexes 33 publications with 361 citations (h-index 7); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6701 Fannin St
Houston, TX 770302316
Telephone
832-822-4240Registry record last updated 25 Mar 2011.
Clinical trials
- ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Sponsor: National Cancer Institute (NCI)
- Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Sponsor: Baylor College of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Cardinal Health 110 LLCProgram year20251 payment
- GENZYME CORPORATIONProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2006–2009 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Clinical and Biological Landscape of Constitutional Mismatch Repair Deficiency: An IRRDC Study
SSRN Electronic Journal
2023 - Relationship between efficacy of phase I/II drug ispinesib in medulloblastoma, molecular subtypes, and p53-mutant status.
Journal of Clinical Oncology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Christopher Caldarone, MD
Baylor University
Hormozd Bozorgchami, MD
Baylor University
Jennifer Rasmussen-Winkler, MD
Baylor University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”